Innate Pharma Archives -

AstraZeneca has abandoned a phase 3 trial of its experimental immuno-oncology candidate monalizumab in head and neck cancer,

AZ, Innate’s checkpoint inhibitor monalizumab flunks phase 3 test

https://pharmaphorum.com/news/az-innates-checkpoint-inhibitor-monalizumab-flunks-phase-3-test/

Clinical-stage oncology biotech Innate Pharma is on a mission to harness the power of natural killer cells to

The next generation of immunotherapy? Innate Pharma targets NK cells

https://pharmaphorum.com/views-and-analysis/the-next-generation-of-immunotherapy-innate-pharma/

France’s Innate Pharma has gained rights to AstraZeneca’s recently approved leukaemia drug Lumoxiti, in a deal that expands

Innate Pharma gains rights to AZ’s recently approved leukaemia drug

https://pharmaphorum.com/news/innate-pharma-gains-rights-to-azs-recently-approved-leukaemia-drug/

Doubts over future of cancer immunotherapy

Future uncertain for Innate and BMS’ troubled lirilumab

https://pharmaphorum.com/news/future-uncertain-innate-bms-troubled-lirilumab/

French biotech developing cancer immunotherapy with BMS.

Innate and BMS’ immunotherapy fails in phase 2 trial

https://pharmaphorum.com/news/innates-immunotherapy-fails-phase-2-aml-trial/

But BMS dumps combination with Yervoy.

Some good news for BMS with Opdivo + natural killer cell combination

https://pharmaphorum.com/news/bms-combine-opdivo-next-gen-immunotherapy/

Innate Pharma